OSI-906 in clinical trial for adrenocortical carcinoma

SCOTTSDALE, Ariz., Sept. 22 /PRNewswire-USNewswire/ -- TGen Clinical Research Services at Scottsdale Healthcare today announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands.

TCRS is a strategic alliance between the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.

Other than...

admin

Gene-Expression Profiling Predicts Tumour Recurrence and Survival for Patients With Adrenocortical Tumours: Presented at ECE

By Chris Berrie

ISTANBUL, Turkey -- April 29, 2009 -- Routine analysis for the expression of 2 specific 2-gene combinations in patients with adrenocortical tumours can reliably predict the risk of tumour recurrence independent of pathology and can also predict the risk of death independent of tumour stage, according to research presented here at the...

admin

Minimally Invasive Adrenalectomy Not Inferior to Open Adrenalectomy in Prognosis of Patients With Small Adrenocortical Carcinomas: Presented at ECE

By Chris Berrie

ISTANBUL, Turkey -- April 27, 2009 -- When comparing minimally invasive adrenalectomy and open adrenalectomy, the prognosis for patients with adrenocortical carcinoma (ACC) of 10 cm or less does not differ, researchers stated here at the 11th European Congress of Endocrinology (ECE).

Similarly, although...

admin

ScienceDaily (Nov. 3, 2008) — An interdisciplinary team of researchers, headed by Ernest Giralt at the Institute for Research in Biomedicine (IRB Barcelona) and Javier de Mendoza at the "Institut Català d’Investigació Química" (ICIQ, Tarragona), have discovered a substance with the capacity to maintain protein p53 stable and active even when it presents certain mutations that promote the appearance of cancer.

Giralt, head of the Chemistry and Molecular Pharmacology programme...

admin